BONDLIDO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BONDLIDO (BONDLIDO).
Lidocaine is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses.
| Metabolism | Primarily metabolized in the liver via oxidative N-dealkylation (CYP1A2, CYP3A4) to monoethylglycinexylidide (MEGX) and glycinexylidide (GX). |
| Excretion | Primarily renal (90% as unchanged drug), minor biliary (<5%) |
| Half-life | Terminal half-life 2.5–3.5 hours; moderately prolonged in renal impairment (up to 6–8 hours) |
| Protein binding | 98–99% to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | Vd approximately 0.5–1.0 L/kg; extensive tissue distribution with high lipophilicity |
| Bioavailability | Oral: 15–25% (first-pass effect); sublingual: 30–50%; rectal: 25–35%; intravenous: 100% |
| Onset of Action | Intravenous: 5–15 minutes; oral: 30–60 minutes (tablet) or 15–30 minutes (oral solution); sublingual: 10–20 minutes |
| Duration of Action | Intravenous: 2–4 hours; oral: 4–6 hours; sublingual: 3–5 hours; prolonged-release formulations: up to 12 hours |
Bupivacaine hydrochloride 10 mg/mL via infiltration or nerve block: maximum total dose 225 mg (without epinephrine) or 300 mg (with epinephrine 1:200,000). Repeat doses no sooner than every 3 hours. Maximum daily dose: 400 mg.
| Dosage form | SYSTEM |
| Renal impairment | No specific dose adjustment required for mild-to-moderate renal impairment (GFR ≥30 mL/min). For GFR <30 mL/min or dialysis, consider cautious dosing due to potential accumulation; monitor for systemic toxicity. |
| Liver impairment | Child-Pugh Class A: No dose adjustment. Child-Pugh Class B: Reduce dose by 50% and monitor for toxicity. Child-Pugh Class C: Avoid use due to impaired clearance; alternative agent recommended. |
| Pediatric use | Infiltration or nerve block: 0.5-2 mg/kg, maximum single dose 2 mg/kg. Maximum total dose adjusted per weight: for age ≤6 months or <10 kg, maximum 2 mg/kg; for age >6 months, maximum 2-4 mg/kg (not to exceed adult maximum). |
| Geriatric use | Initiate at lower end of dosing range due to age-related decreases in hepatic clearance and increased risk of toxicity. Dose reductions of 25-50% recommended for patients >65 years, especially those with comorbidities. Monitor for prolonged effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BONDLIDO (BONDLIDO).
| Breastfeeding | Lidocaine is excreted into breast milk in small amounts (M/P ratio ~0.4-0.6), not expected to cause adverse effects in full-term infants with normal hepatic function. However, consider risk of lidocaine metabolite accumulation in neonates with immature hepatic function. |
| Teratogenic Risk | FDA Category C: Lidocaine crosses placenta. In first trimester, limited data; avoid unless benefit outweighs risk. Second and third trimesters: use with caution; fetal bradycardia and CNS depression possible with high doses or prolonged use. Paracervical block in early pregnancy associated with fetal acidosis. |
■ FDA Black Box Warning
WARNING: Convulsions and cardiovascular collapse may occur if excessive systemic absorption occurs. Use the lowest dose that provides effective anesthesia. Do not inject intravascularly. Resuscitative equipment and drugs for treatment of toxic reactions must be immediately available.
| Serious Effects |
["Hypersensitivity to lidocaine, other amide anesthetics, or any component of the formulation.","Severe hypotension or complete heart block."]
| Precautions | ["Risk of methemoglobinemia, especially with concurrent use of oxidizing agents.","Use with caution in patients with liver disease, renal impairment, or cardiac disease (e.g., bradycardia, heart block).","Monitor for signs of systemic toxicity: circumoral numbness, tinnitus, blurred vision, seizures, arrhythmias.","Avoid application to broken or inflamed skin."] |
| Food/Dietary | No food interactions have been identified with topical lidocaine. No dietary restrictions required. |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, ECG for signs of toxicity. Fetal heart rate tracing recommended during intrapartum use. Assess neonatal Apgar scores, respiratory effort, and tone after delivery if systemic lidocaine used near term. Signs of CNS depression, bradycardia, or methemoglobinemia in neonate. |
| Fertility Effects | No human data on fertility effects. In animal studies, no significant impairment of fertility observed at clinically relevant doses. Lidocaine not known to affect sperm parameters or ovulation. |
| Clinical Pearls | BONDLIDO (lidocaine topical patch) provides local analgesia for postherpetic neuralgia. Apply to intact skin only; do not use on open wounds or mucous membranes. Limit to 1 patch at a time for up to 12 hours per day. Remove patch if excessive burning or irritation occurs. Monitor for lidocaine toxicity (perioral numbness, metallic taste) especially in patients with hepatic impairment or those on antiarrhythmics like mexiletine. |
| Patient Advice | Apply the patch only to intact, clean, dry skin over the painful area. · Do not use more than 1 patch at a time or wear it longer than 12 hours in a 24-hour period. · Wash hands after applying the patch and avoid touching eyes. · Do not expose the area to heat sources (heating pads, direct sunlight) as it may increase absorption. · Store patches at room temperature and keep out of reach of children and pets. · If you experience severe burning, itching, or swelling at the application site, remove the patch and contact your healthcare provider. · Do not use if you are allergic to lidocaine or other local anesthetics. · Inform your doctor if you have severe liver disease or are taking heart rhythm medications. |